Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882013 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL13134791 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL14644648 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL12966927 | 0.85 | POLB (0.38) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL800360 | 0.84 | CYP3A4 (0.41) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL14929281 | 0.83 | P2RY2 (0.40) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL23348448 | 0.82 | POLB (0.47) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL14853784 | 0.82 | POLB (0.47) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL13471844 | 0.82 | POLB (0.47) | CYP3A4CYP2C9POLBHSD17B10MEN1 | |
| SCHEMBL1828639 | 0.82 | POLB (0.47) | CYP3A4CYP2C9POLBHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | CYP3A4 3278/4885CYP2C9 3385/4885POLB 119/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | CYP3A4 3324/4885CYP2C9 3026/4885POLB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.